Delirium Quetiapine Delirirum Prevention Hospitalized Internal medicine Elderly
Conditions
Interventions
Quetiapine 12.5 mg tablets once daily at 9 pm for a maximum of seven consecutive days.,Placebo once daily at 9 pm for a maximum of seven consecutive days.
Experimental Drug,Placebo Comparator Drug
Sponsors
Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Patient aged more than 65 years, acutely hospitalized in a medical ward.
Exclusion criteria
Exclusion criteria: Patient or family refusal, patient who was diagnosed delirium, patient who was critically ill, emergency surgery, terminal illness, unable to take medication, currently taking antipsychotics, active cardiac conditions, history of epilepsy, substance dependence or abuse, blood potassium level ≤ 3.0 mEq/L, corrected QTc ≥ 500 msec from EKG, unable to communicate, expected to be discharged within 24 hours, severe Parkinson’s disease and patient who was diagnosed dementia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delirium incident During intervention Confusion Assessment Method (CAM),Delirium duration During intervention Confusion Assessment Method (CAM) | — |
Secondary
| Measure | Time frame |
|---|---|
| Delirium duration During intervention Confusion Assessment Method (CAM),ICU admission During hospital admission Patient is transferred to ICU,Mortality During hospital admission Patient death during hospital admission,Rehospitalization 90 days after patient discharge Patient record review and telephone,90-day mortality 90 days after patient discharge Patient record review and telephone | — |
Countries
Thailand
Contacts
Public ContactSaran Thanapluetiwong
Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
Outcome results
None listed